Human sexual health represents a complex nexus of physiological integrity, neurobiological signaling, psychological well-being, and relational dynamics. When disruptions occur within the neurochemical and somatic pathways that mediate sexual culmination, the resulting condition often manifests as anorgasmia, a clinically significant impairment characterized by the persistent inability to reach climax despite adequate stimulation. This profound sexual dysfunction can fundamentally undermine self-esteem, interpersonal intimacy, and overall quality of life, necessitating a rigorous biopsychosocial approach to diagnosis and clinical remediation.
Anorgasmia
1. Concise Definition
Anorgasmia is an established sexual dysfunction characterized by the persistent or recurrent delay in, or complete absence of, orgasm following a normal sexual excitement phase, occurring despite adequate focus, intensity, and duration of sexual stimulation. Under standard diagnostic frameworks, the condition must cause clinically significant distress or interpersonal difficulty and cannot be better accounted for by another non-sexual psychiatric disorder, severe relationship distress, or the direct physiological effects of a substance or general medical condition.
In psychiatric nosology, such as the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR), the condition is primarily operationalized as Female Orgasmic Disorder when presenting in biological females, and as Delayed Ejaculation or orgasmic absence in biological males. The International Classification of Diseases, Eleventh Revision (ICD-11), designates corresponding categories under Orgasmic Dysfunctions, emphasizing that the absence or marked infrequency of orgasmic experience must persist for a minimum of approximately six months to meet diagnostic thresholds.
Crucially, clinical definitions distinguish true anorgasmia from variations in normal sexual response. For instance, the inability of a female individual to achieve orgasm solely through penetrative coitus without concomitant clitoral stimulation is recognized as a normative physiological variation rather than a medical pathology. Thus, diagnostic accuracy hinges upon assessing whether the orgasmic inhibition occurs in the presence of stimulation that the individual considers subjective, erotically stimulating, and physically adequate.
2. Etymology & Linguistic Origin
The term anorgasmia derives from classical Greek roots via modern medical Latin and French lexical adaptations. The prefix an- (Greek: ἀν-) functions as an alpha privative, denoting negation, absence, or lack. The root stem corresponds to the Greek noun orgasmos (ὀργασμός), which translates literally to “excitement,” “swelling,” or “lustful passion,” and is intimately linked to the verb organ (ὀργᾶν), meaning “to swell with moisture,” “to grow ripe,” or “to be eager or lustful.”
Historically, the term orgasme was introduced into French clinical and philosophical discourse in the sixteenth and eighteenth centuries to describe extreme paroxysms of passion, emotional swelling, and physiological climax. By the mid-twentieth century, sexologists and clinical psychoanalysts hybridized the Greek privative prefix with the established noun orgasm to form anorgasmia. This linguistic coinage provided a neutral, clinical descriptor to replace outdated, moralistic, or pathologizing Victorian terminology such as “frigidity,” thereby repositioning orgasmic inhibition firmly within objective psychosexual medicine.
3. Pronunciation & Grammatical Form
The standard phonetic transcription of the term in International Phonetic Alphabet (IPA) format is /ˌæn.ɔːrˈɡæz.mi.ə/ in General American English and /ˌæn.ɔːˈɡæz.mi.ə/ in Received Pronunciation. Primary stress falls upon the third syllable (“-gaz-“), while secondary stress rests on the initial syllable (“an-“).
Grammatically, the term operates as an uncountable abstract noun. The related adjectival form is anorgasmic (/ˌæn.ɔːrˈɡæz.mɪk/), used to describe an individual experiencing the dysfunction (e.g., “an anorgasmic patient”) or conditions associated with it (e.g., “an anorgasmic state”). The derived adverbial form is anorgasmically. Clinicians also utilize descriptive qualifiers such as “primary,” “secondary,” “situational,” or “generalized” to classify specific presentations of the noun within medical documentation.
4. Detailed Conceptual Explanation
To fully conceptualize anorgasmia, one must examine the multi-phased nature of the human sexual response cycle. Classically modeled by William Masters and Virginia Johnson, and later modified by Helen Singer Kaplan and Rosemary Basson, this cycle transitions through desire, subjective and physiological arousal, orgasm, and resolution. Anorgasmia represents a discrete failure of the third phase—the orgasmic climax—despite the subjective presence of desire and the physiological attainment of arousal (such as vasocongestion, vaginal lubrication, and penile or clitoral tumescence).
Neurobiologically, orgasm is a complex neuro-reflexive event coordinated by the autonomic, somatic, and central nervous systems. Peripheral sensory input generated via mechanoreceptors in the clitoris, glans penis, perineum, or surrounding erogenous tissues travels via the pudendal and pelvic nerves to the sacral spinal cord (S2–S4). From the spinal reflex arc, ascending signals traverse spinothalamic tracts to activate cerebral structures, including the paraventricular nucleus of the hypothalamus, the medial preoptic area, the thalamus, the amygdala, and the reward circuitry centered on the nucleus accumbens.
At climax, a synchronized efferent discharge triggers rhythmic, involuntary contractions of the perineal striated musculature (specifically the bulbocavernosus and ischiocavernosus muscles), the pelvic floor, and, in males, the prostate and vas deferens. Simultaneously, massive neurochemical surges occur, predominantly involving oxytocin, endogenous opioids, and dopamine, accompanied by a post-orgasmic release of prolactin, which induces systemic satiety.
In anorgasmia, this delicate synchrony fails. Inhibitory mechanisms override excitatory cascades. At the central level, elevated serotonergic (5-HT) tone—frequently observed during treatment with selective serotonin reuptake inhibitors (SSRIs)—downregulates central dopamine and norepinephrine signaling, preventing the neurochemical threshold required for climax from being reached. Peripherally, neuropathies (such as those stemming from poorly controlled diabetes mellitus or pelvic surgeries) may impair afferent somatosensory transmission. Psychologically, sympathetic autonomic hyperarousal, often driven by anticipatory performance anxiety, can disrupt the balance of parasympathetic dominance necessary for arousal and the subsequent sympathetic surge required to initiate the orgasmic reflex.
5. Historical Development
The medical and psychoanalytic understanding of orgasmic dysfunction has undergone substantial transformation over the past two centuries:
- The Nineteenth Century and Victorian Medicine: Female orgasmic incapacity was rarely conceptualized as a medical disorder because prevailing sociocultural doctrines minimized female sexual agency. Instead, sexual complaints were subsumed under the nebulous diagnosis of “hysteria,” which physicians treated using pelvic massage to induce “hysterical paroxysms” without recognizing them as genuine orgasms.
- Freudian Psychoanalysis (Early 20th Century): Sigmund Freud introduced a theoretical dichotomy between “clitoral” and “vaginal” orgasms. Freud posited that healthy psychosexual development required a mature woman to transfer her primary erogenous locus from the clitoris to the vagina. Women who could only achieve climax through clitoral stimulation were pathologized as emotionally immature, neurotic, or “frigid.” This theoretical construct generated pervasive clinical misconceptions that persisted for decades.
- The Masters and Johnson Revolution (1966): The empirical laboratory investigations of William Masters and Virginia Johnson irrevocably debunked Freud’s dual-orgasm theory. Using physiological monitoring, they proved that all female orgasms are fundamentally identical in their physiological manifestation—involving rhythmic contractions of the circumvaginal musculature—regardless of whether stimulation originates from direct clitoral manipulation, vaginal penetration, or other erogenous zones. They legitimized clitoral stimulation as the primary anatomic trigger for female orgasm.
- Nosological Standardization (1970s–Present): In 1974, Helen Singer Kaplan formulated a triphasic model of sexual response (desire, arousal, orgasm) that directly influenced modern psychiatric categorization. With the publication of the DSM-III (1980), the stigmatizing label “frigidity” was permanently discarded in favor of “Inhibited Female Orgasm” and “Inhibited Male Orgasm.” Subsequent iterations, through the DSM-5-TR, refined these categories into Female Orgasmic Disorder and Delayed Ejaculation, establishing strict operational criteria requiring clinically significant distress and a six-month duration threshold.
6. Theoretical Foundations
Modern clinical sexology analyzes anorgasmia through several robust theoretical lenses:
The Biopsychosocial Model: Formulated broadly by George Engel and adapted to sexual medicine by contemporary clinicians, this model posits that anorgasmia cannot be reduced purely to organic lesions or intrapsychic conflict. It conceptualizes the disorder as an emergent property of interacting biological elements (hormonal balance, neurochemistry, vascular health), psychological elements (body image, past trauma, mood disorders), and sociocultural variables (partner dynamics, religious guilt, sexual scripts). Effective assessment must evaluate all three domains concurrently.
Cognitive-Behavioral Frameworks: Cognitive theories emphasize the destructive role of “spectatoring,” a concept originally identified by Masters and Johnson. Spectatoring occurs when an individual adopts a detached, self-monitoring, evaluative third-person perspective during intimate acts. This heightened self-surveillance generates performance anxiety and activates the sympathetic nervous system (“fight or flight”). Because sexual arousal and the progression toward climax require sustained attentional focus on erotic sensory stimuli, cognitive interference interrupts the requisite neurophysiological cascade.
Evolutionary Perspectives: Evolutionary theorists actively debate the evolutionary function of the female orgasm. One school of thought, the adaptationist model, argues that the female orgasm evolved as an adaptive mechanism to promote pair-bonding, facilitate mate selection, or enhance reproductive success via post-coital uterine contractions that aid sperm retention. Conversely, the non-adaptationist or “by-product” (spandrel) hypothesis, championed by Donald Symons and Stephen Jay Gould, posits that the female orgasm is an embryological homologue of the male orgasm—adaptive in males for ejaculation, but retained in females without direct selective pressure. Under the spandrel hypothesis, variability in female orgasmic capacity is viewed not as a biological disease state, but as natural biological diversity.
7. Key Components, Types & Dimensions
Anorgasmia is not a monolithic condition; clinicians classify it according to several key diagnostic dimensions and subtypes:
- Primary (Lifelong) Anorgasmia: The individual has never experienced an orgasm under any circumstances, whether through coitus, manual stimulation, oral sex, or solitary masturbation. This form frequently indicates deeper physiological anomalies, significant developmental or religious conditioning, or profound psychological inhibitions.
- Secondary (Acquired) Anorgasmia: The person previously possessed the capacity to reach climax but subsequently lost this ability. Acquired anorgasmia is highly correlated with pharmacological interventions (such as initiating SSRIs), endocrine disruptions, neurological disorders, relationship distress, or traumatic experiences.
- Generalized (Global) Anorgasmia: The orgasmic incapacity occurs across all sexual situations, with all partners, and during solitary sexual activity (e.g., masturbation or nocturnal emissions). This presentation strongly raises suspicion of an underlying organic, neurological, or medication-induced etiology.
- Situational Anorgasmia: The individual can achieve orgasm under specific conditions (e.g., solitary masturbation, using a high-intensity vibrator) but is entirely unable to do so under other circumstances (e.g., partnered intercourse, or with a specific partner). Situational anorgasmia represents the vast majority of clinical presentations and points heavily toward psychological, relational, or stimulatory insufficiencies.
- Iatrogenic or Substance-Induced: Inhibition of orgasm directly attributable to the introduction of exogenous chemical agents, particularly psychotropic medications, antihypertensives, or chronic alcohol and substance abuse.
8. Examples & Illustrative Cases
The following case presentations illustrate the heterogeneous clinical expressions of anorgasmia across different populations and etiologies:
Case Illustration 1: Primary Situational Anorgasmia
A 26-year-old cisgender woman presents to an outpatient sexual health clinic reporting that she has never achieved orgasm with her long-term partner during their four-year relationship. However, she reports reaching intense climaxes within three to five minutes during solitary masturbation using direct clitoral manual stimulation. Comprehensive sexual history reveals that the couple engages almost exclusively in unassisted penile-vaginal intercourse, with minimal foreplay and no direct clitoral stimulation during coitus. The patient harbors internal cognitive scripts suggesting that “mature” women should climax through intercourse alone, leading to intense performance anxiety and spectatoring during partnered sex. Psychoeducation regarding clitoral anatomy, coupled with couples communication training and the integration of clitoral stimulation during intercourse, successfully resolved the complaint.
Case Illustration 2: Acquired Generalized Iatrogenic Anorgasmia
A 42-year-old cisgender male with a history of recurrent major depressive disorder was initiated on 20 mg of escitalopram daily. Within three weeks of reaching the therapeutic dose, he noted a complete remission of his depressive symptomatology, accompanied by preserved sexual desire and normal erectile function. However, he developed absolute anorgasmia: despite prolonged masturbatory or partnered stimulation lasting upwards of forty-five minutes, he could not reach ejaculatory climax, leading to physical exhaustion and genital discomfort. After cross-titrating from escitalopram to bupropion—an atypical antidepressant operating primarily on norepinephrine and dopamine reuptake—his orgasmic capacity returned to baseline within ten days.
9. Measurement & Assessment
Comprehensive assessment of anorgasmia requires a multi-method protocol combining clinical interviews, validated psychometric instruments, and medical examinations:
Clinical Diagnostic Interview: The clinician must obtain a granular psychosexual history, establishing the timeline of the dysfunction (lifelong vs. acquired), context (situational vs. generalized), subjective distress levels, and the precise mechanical nature of stimulation utilized. It is paramount to screen for relationship satisfaction, sexual trauma history, and religious or cultural beliefs surrounding sexual pleasure.
Psychometric Rating Scales: Standardized self-report questionnaires provide objective benchmarking of orgasmic function. For female patients, the Female Sexual Function Index (FSFI) is the gold standard, containing a dedicated three-item orgasmic domain evaluating frequency, difficulty, and satisfaction. For male patients, the International Index of Erectile Function (IIEF) contains an orgasmic function domain assessing ejaculation and orgasmic frequency. Additional tools include the Golombok Rust Inventory of Sexual Satisfaction (GRISS) and the Arizona Sexual Experience Scale (ASEX).
Physical and Laboratory Diagnostics: When acquired or generalized anorgasmia is suspected, physical evaluation is essential. Laboratory tests routinely evaluate serum levels of total and free testosterone, estradiol, prolactin, thyroid-stimulating hormone (TSH), and fasting blood glucose (to rule out diabetic autonomic neuropathy). In specialist neuro-urological settings, biothesiometry may be employed to assess vibratory sensation thresholds across the genital branches of the pudendal nerve.
10. Applications & Practical Significance
Addressing anorgasmia holds widespread clinical, therapeutic, and societal significance across multiple disciplines:
Clinical Sex Therapy: For primary and situational female anorgasmia, directed masturbation therapy, pioneered by Joseph LoPiccolo and Lonnie Barbach, remains the first-line, empirically supported psychological intervention. This structured, progressive behavioral program guides the individual through body exploration, desensitization of sexual guilt, the introduction of focused manual and mechanical (vibratory) clitoral stimulation, and eventual partner integration using sensate focus exercises.
Pharmacological Optimization: In psychiatric settings, managing SSRI-induced sexual dysfunction is a primary driver of treatment adherence. Abrupt discontinuation of antidepressants due to orgasmic failure carries severe risks of depressive relapse. Knowledge of pharmacology allows clinicians to employ strategies such as “drug holidays,” dose reductions, switching to non-serotonergic agents (e.g., bupropion, mirtazapine, vilazodone), or augmenting with phosphodiesterase-5 (PDE5) inhibitors or cyproheptadine.
Pelvic Floor Rehabilitation: Pelvic health physical therapy plays an expanding role in treating orgasmic disorders. Hypertonic (overly tight) or hypotonic (weak) pelvic floor musculature can mechanically impair the rhythmic contractions of the bulbocavernosus and pubococcygeus muscles. Electromyographic (EMG) biofeedback and targeted pelvic floor physical therapy facilitate the neuromuscular coordination required for complete climax.
11. Research & Empirical Evidence
Epidemiological research reveals that orgasmic difficulties are among the most prevalent sexual complaints worldwide, particularly among women. Landmark population-based investigations, such as the National Health and Social Life Survey conducted by Edward Laumann and colleagues, indicated that approximately 24% to 30% of women in the United States report persistent difficulty achieving orgasm, while male delayed ejaculation or male anorgasmia affects approximately 3% to 8% of the male population.
Modern neuroimaging research, led by investigators such as Barry Komisaruk, Janniko Georgiadis, and Gert Holstege, has utilized functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET) to map cerebral activation patterns during orgasm. These studies demonstrate that orgasm induces profound, transient deactivation of the left temporal lobe and the prefrontal cortex—regions associated with self-monitoring, analytical judgment, and social inhibition—accompanied by profound activation in the limbic system, cerebellum, and sensory cortex. This empirical neuroimaging data supports clinical models suggesting that the inability to achieve down-regulation of prefrontal executive control (i.e., failure to “let go” of analytical oversight) plays a direct neurofunctional role in psychogenic anorgasmia.
In pharmacological literature, comprehensive meta-analyses by researchers like Angel Montejo have documented that sexual dysfunction occurs in 58% to 70% of patients treated with conventional SSRIs, with orgasmic delay or total anorgasmia representing a primary complaint. These robust empirical findings have led directly to modern prescribing guidelines that emphasize proactive assessment of orgasmic function before and during psychotropic pharmacotherapy.
12. Cultural & Cross-Cultural Considerations
Cultural norms, systemic gender expectations, and religious orthodoxy heavily dictate how orgasmic difficulty is experienced, reported, and treated:
- The “Orgasm Gap”: Sociological studies consistently demonstrate an empirical disparity in orgasmic frequency between heterosexual men and heterosexual women during partnered sexual encounters. Sociological analysis attributes this not to intrinsic biological deficits in women, but to prevailing cultural “sexual scripts” that prioritize coitus and male ejaculation while neglecting clitoral stimulation. In contrast, studies among lesbian women reveal significantly higher rates of orgasmic frequency during partnered sex, highlighting the profound role of technique, communication, and social conditioning over innate biology.
- Religious and Moral Conditioning: Subcultures that enforce strict sexual purity doctrines, associate female sexual pleasure with sinfulness, or prohibit solitary masturbation exhibit higher baseline rates of primary psychogenic anorgasmia. Individuals raised within such environments frequently internalize shame, creating persistent involuntary pelvic floor hypertonicity and cognitive intrusion that block sexual arousal.
- Diagnostic Pathologization Across Cultures: What constitutes a “disorder” varies globally. In cultures where female sexual function is viewed exclusively through the lens of procreation and familial duty, personal orgasmic absence may not generate subjective distress or prompt clinical presentation. Conversely, in highly individualistic societies where sexual self-actualization is heavily emphasized in popular media, normal episodic delays in climax may be prematurely pathologized as medical failure, driving profound performance anxiety.
13. Criticisms, Debates & Limitations
The conceptualization of anorgasmia within clinical medicine remains subject to vigorous intellectual debate:
The Medicalization of Normative Diversity: Numerous feminist theorists and medical anthropologists criticize the psychiatric diagnostic manuals (DSM and ICD) for medicalizing women’s bodies. They argue that categorizing the inability to achieve coital orgasm as a clinical pathology inappropriately frames a basic anatomic reality—the fact that the clitoris, rather than the internal vaginal canal, is the primary organ of female orgasmic pleasure—as a medical deficit. Although modern DSM criteria require inadequate response to “stimulation deemed adequate,” critics argue that clinical practice still frequently labels women as disordered when their partners merely fail to provide necessary stimulation.
The Validity of the “Distress Criterion”: Psychiatric nosology requires that the inability to climax cause “marked distress or interpersonal difficulty” to qualify as anorgasmia. Scholars debate whether this distress originates internally from a biological drive for physical release or is socially constructed by cultural pressures mandating that every sexual encounter culminate in climax. When an individual enjoys sexual intimacy, feels fulfilled, but does not reach orgasm, imposing a medical diagnosis based on external partner expectations can lead to iatrogenic distress.
Ejaculation vs. Orgasm in Males: A persistent conceptual debate in male sexual medicine involves separating the physiological mechanism of ejaculation (emission and expulsion of semen) from the subjective, neurosensory experience of orgasm. While these events typically occur synchronously, conditions such as orgasmic anejaculation (orgasm without fluid release) and anorgasmic ejaculation (ejaculatory expulsion without subjective orgasmic sensation or pleasure, termed “pleasureless ejaculation” or sexual anhedonia) demonstrate that they are governed by distinct neurochemical mechanisms. Conflating delayed ejaculation with male anorgasmia limits precise clinical taxonomy.
14. Related Terms & Distinctions
To avoid diagnostic errors, anorgasmia must be distinguished from several interrelated conditions and clinical phenomena:
- Hypoactive Sexual Desire Disorder (HSDD): Characterized by a persistent deficiency or absence of sexual fantasies and desire for sexual activity. In contrast, individuals with pure anorgasmia typically maintain normal libido, desire, and interest in sexual activity, but face a blockage at the climax phase.
- Sexual Arousal Disorders: Refers to the inability to attain or maintain adequate physiological arousal (e.g., erectile dysfunction in men, or lack of lubrication and genital swelling in women). Anorgasmic individuals frequently achieve robust, sustained arousal, yet cannot bridge the threshold from excitation to orgasm.
- Dyspareunia and Genito-Pelvic Pain/Penetration Disorder (GPPPD): Characterized by persistent pain during attempted or completed vaginal penetration. While chronic sexual pain frequently leads to secondary anorgasmia due to involuntary muscle guarding and fear conditioning, they represent distinct clinical entities.
- Sexual Anhedonia (Ejaculatory Anhedonia): A condition wherein the physical manifestations of orgasm (such as muscular contractions and ejaculation) take place normally, but the individual perceives zero subjective pleasure, euphoria, or reward. Anorgasmia involves the total absence of the physical reflex and its accompanying psychological climax.
- Delayed Ejaculation: The male-specific diagnostic category in the DSM-5-TR, defined as a marked delay in, or infrequency of, ejaculation. While often synonymous with male anorgasmia, some men experience orgasm without ejaculation, making rigorous diagnostic differentiation necessary.
15. Summary / Key Takeaways
Anorgasmia is a multifaceted sexual dysfunction defined by the persistent delay or absence of orgasmic culmination following an adequate phase of sexual excitement, causing measurable personal distress. The condition exists across biological sexes and is classified as primary (lifelong) or secondary (acquired), and generalized or situational. While historically clouded by moralistic judgments and flawed psychoanalytic frameworks, modern clinical medicine recognizes anorgasmia as a legitimate biopsychosocial disorder arising from complex interactions between neurochemical pathways (particularly serotonergic-dopaminergic balance), anatomical and vascular health, cognitive processing (such as spectatoring), and relational dynamics.
Diagnosis relies on rigorous clinical interviewing supported by validated psychometric scales like the FSFI and IIEF, alongside targeted biomedical screening to identify potential endocrine, neurological, or iatrogenic (especially SSRI-induced) causes. Treatment approaches demonstrate high clinical efficacy, ranging from directed masturbation programs and sensate focus therapies in cognitive-behavioral sex therapy, to targeted pelvic floor physical therapy and pharmacological modification. Successful management requires dismantling unrealistic cultural scripts regarding sexual performance and fostering open, anatomically informed communication between partners.
Ultimately, orgasmic capacity is not an isolated metric of mechanical competence, but an integral dimension of human well-being. By integrating neurobiological precision with compassionate, culturally sensitive psychotherapy, clinicians can demystify orgasmic inhibition, alleviate profound interpersonal distress, and help individuals reclaim their fundamental capacity for sexual health and personal fulfillment.
References
- American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed., text rev.). American Psychiatric Association Publishing. https://doi.org/10.1176/appi.books.9780890425787
- Basson, R. (2000). The female sexual response: A different model. Journal of Sex & Marital Therapy, 26(1), 51–65. https://doi.org/10.1080/009262300278641
- Kaplan, H. S. (1974). The new sex therapy: Active treatment of sexual dysfunctions. Brunner/Mazel.
- Laumann, E. O., Paik, A., & Rosen, R. C. (1999). Sexual dysfunction in the United States: Prevalence and predictors. JAMA, 281(6), 537–544. https://doi.org/10.1001/jama.281.6.537
- Masters, W. H., & Johnson, V. E. (1966). Human sexual response. Little, Brown and Company.
- Montejo, A. L., Llorca, G., Izquierdo, J. A., & Rico-Villademoros, F. (2001). Incidence of sexual dysfunction associated with antidepressant agents: A prospective multicenter study of 1022 outpatients. The Journal of Clinical Psychiatry, 62(Suppl 3), 10–21. https://www.psychiatrist.com/jcp/incidence-sexual-dysfunction-associated-antidepressant/
- Rosen, R., Brown, C., Heiman, J., Leiblum, S., Meston, C., Shabsigh, R., Ferguson, D., & D’Agostino, R. (2000). The Female Sexual Function Index (FSFI): A multidimensional self-report instrument for the assessment of female sexual function. Journal of Sex & Marital Therapy, 26(2), 191–208. https://doi.org/10.1080/009262300278597
- World Health Organization. (2019). International statistical classification of diseases and related health problems (11th ed.). World Health Organization. https://icd.who.int/